sdz mrl 953 has been researched along with galactosamine in 2 studies
| Studies (sdz mrl 953) | Trials (sdz mrl 953) | Recent Studies (post-2010) (sdz mrl 953) | Studies (galactosamine) | Trials (galactosamine) | Recent Studies (post-2010) (galactosamine) |
|---|---|---|---|---|---|
| 8 | 1 | 0 | 3,542 | 7 | 704 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aschauer, H; Hildebrandt, J; Lam, C; Liehl, E; Macher, I; Schütze, E; Stütz, P | 1 |
| Hildebrandt, J; Lam, C; Liehl, E; Schütze, E | 1 |
2 other study(ies) available for sdz mrl 953 and galactosamine
| Article | Year |
|---|---|
SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Drug Interactions; Female; Galactosamine; Humans; Lethal Dose 50; Lipid A; Lipopolysaccharides; Mice; Mice, Inbred C57BL | 1991 |
Protection of mice from mortality caused by living and heat-killed bacteria by SDZ MRL 953.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Physiological Phenomena; Female; Galactosamine; Hot Temperature; Immune System; Lipid A; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neutropenia; Shock, Septic; Survival Analysis; Tumor Necrosis Factor-alpha; Vaccines, Inactivated | 1994 |